Neurological Abnormality

2

Review clinical trials related to Neurological Abnormality. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Turkish Version of the BRIEF-Hammersmith Infant Neurological Examination (HINE)

The American Academy of Pediatrics defines high-risk infants as those with preterm birth, special health care needs, family risk factors, and those at risk of early death. Factors such as premature birth, perinatal asphyxia, hypoxic-ischemic encephalopathy (HIE), periventricular leukomalacia (PVL), intraventricular hemorrhage (IVH), chronic lung disease, seizures, meningitis, hyperbilirubinemia, twin/triplet pregnancy, and intrauterine growth restriction are risk factors that can result in morbidity and mortality in infants. Regular neurological examinations and neuromotor tests are necessary for at-risk infants to identify developmental problems early and to initiate early intervention programs.In developing countries, regular follow-up and early rehabilitation of at-risk infants are not successfully implemented. 5,6 The lengthy test batteries and busy clinics are among the most significant reasons. Therefore, the development and dissemination of shorter, valid, and reliable tests is of great importance. The Hammersmith Neonatal Neurological Examination (HINE), one of the gold standard methods, consists of 26 items and takes 15-20 minutes to administer.Due to the number of items and the duration, it is not frequently used routinely. In response to this clinical need, the HINE short scale was developed in 2024.The aim of the study is to have a Turkish version of the Abstract-HINE test in Turkey and to study its validity and reliability in high-risk infants.

Participants needed: 120
Trial details
Age: 3-12Biological sex: AllType: ObservationalSponsor: Kahramanmaras Sutcu Imam UniversityUpdated: Sep 19, 2025Locations: 1Duration: 1 Year
Eligibility criteria

Infants with high risk of CP: Periventricular hemorrhage, intracranial hemorrhag...

Infants with any known orthopedic, systemic disease or neurological diagnosis ot...

Status: Recruiting

Pilot Study of ZetaFuse™ Bone Graft for the Treatment of Cervical Degenerative Disc Disease

The goal of this pilot clinical trial is to test the safety and preliminary performance of the ZetaFuse Bone Graft in patient requiring fusion of the C3-C7 vertebral bones due to pain or loss of neurological function. Participants will be treated with ZetaFuse during surgical intervention to reduce pain and the loss of neurological function.

Participants needed: 10
Trial details
Age: 22-75Biological sex: AllType: InterventionalSponsor: Zetagen Therapeutics, IncUpdated: Apr 24, 2025Locations: 2
Eligibility criteria

Age 22 to 75 years (inclusive) at the time of enrollment. [+18]

A cervical spinal condition other than symptomatic cervical degenerative disc di... [+26]